Paraneoplastic Neurologic Disorders
Paraneoplastic neurologic syndromes are clinical manifestations of an ongoing antitumor immune response targeting neural antigens expressed by tumors (onconeural antigens). These disorders often present before the underlying cancer is clinically evident, making neurologic evaluation the first opportunity for cancer diagnosis. The field has been transformed by the discovery of disease-specific neural antibodies that guide diagnosis, direct cancer screening, and inform treatment decisions. The 2021 revised paraneoplastic criteria introduced a scoring system (PNS-Care Score) incorporating clinical phenotype risk, antibody risk, and cancer status to improve diagnostic accuracy.
Bottom Line
- Mechanism: Antitumor immune response cross-reacting with neural antigens; intracellular antigen antibodies indicate T-cell-mediated neuronal destruction (often irreversible); cell-surface antibodies indicate antibody-mediated dysfunction (potentially reversible)
- High-risk phenotypes: Rapidly progressive cerebellar ataxia, sensory neuronopathy, encephalomyelitis, opsoclonus-myoclonus, Lambert-Eaton myasthenic syndrome
- Key antibodies: ANNA-1 (Hu) → SCLC; PCA-1 (Yo) → ovarian/breast; KLHL11/Ma2 → germ cell tumors; SOX1 → SCLC with LEMS
- Cancer screening: CT body, PET-CT; screening should continue for ≥2 years if initial evaluation is negative
- Treatment: Tumor removal is the most critical intervention; immunotherapy (corticosteroids, IVIg, PLEX, rituximab, cyclophosphamide) is supplementary
- ICI-related neurotoxicity: Immune checkpoint inhibitor therapy can trigger or unmask paraneoplastic neurologic syndromes
Immunologic Mechanisms
Cancer Immunoediting
The relationship between cancer and the immune system follows the three-phase immunoediting model:
- Elimination: Innate and adaptive immunity destroy early cancer cells; tumor is clinically occult
- Equilibrium: Adaptive immunity keeps surviving cancer cells dormant; paraneoplastic neurologic syndrome may present during this phase, before cancer is diagnosed
- Escape: Cancer cells evade immune surveillance and become clinically evident
Patients may present to neurologists with paraneoplastic neurologic syndromes during the elimination or equilibrium phase — often before the oncologist identifies the cancer.
Two Effector Mechanisms
| Feature | Intracellular Antigen (T-cell effector) | Cell-Surface Antigen (Antibody effector) |
|---|---|---|
| Mechanism | CD8+ cytotoxic T cells target cells displaying specific peptides on MHC-I | IgG antibodies directly impair receptor/channel function |
| Tissue damage | Irreversible neuronal death | Often reversible dysfunction |
| Antibody role | Biomarker only | Directly pathogenic |
| Immunotherapy response | Poor (neurons already destroyed) | Often good |
| Key treatment | Tumor removal; T-cell directed agents (cyclophosphamide, mycophenolate) | Tumor removal + B-cell/antibody-directed agents (rituximab, PLEX, IVIg) |
| Examples | ANNA-1, PCA-1, KLHL11, Ma2, amphiphysin | NMDA-R, GABAB-R, AMPA-R, CASPR2 |
High-Risk Paraneoplastic Phenotypes
Rapidly Progressive Cerebellar Degeneration
- Weeks-to-months progression of severe cerebellar ataxia, often leading to wheelchair dependence within 3 months
- PCA-1 (Yo): F:M 1:20; 90% with breast, ovarian, or mullerian cancer; poor prognosis (most wheelchair-bound within 3 months)
- ANNA-1 (Hu): Often multifocal; 80% SCLC
- Ma2 (only): Young men (median late 30s); 90% with germ cell tumors (seminoma); limbic + diencephalic + brainstem involvement; sleep disorders
- KLHL11: M:F 99:1; mid-40s; rhombencephalitis with hearing loss; 80% germ cell tumors; poor prognosis (25% mortality at 1 year)
Sensory Neuronopathy (Dorsal Root Ganglionopathy)
- Rapidly progressive severe sensory loss, ataxia, areflexia — the original paraneoplastic syndrome described by Denny-Brown (1948)
- ANNA-1 (Hu): 80% with SCLC; non-length-dependent sensory loss pattern; nerve conduction studies show absent or reduced SNAPs with normal motor studies
- Often progresses to multifocal involvement (encephalomyeloneuropathy)
Lambert-Eaton Myasthenic Syndrome (LEMS)
- Antibodies against P/Q-type voltage-gated calcium channels (VGCC)
- Proximal weakness, hyporeflexia with post-exercise facilitation, autonomic dysfunction (dry mouth)
- SOX1 antibodies: Highly associated with paraneoplastic LEMS due to SCLC
- ~60% paraneoplastic (SCLC); ~40% autoimmune (non-paraneoplastic)
Opsoclonus-Myoclonus Syndrome
- Involuntary, conjugate, arrhythmic, multidirectional saccadic eye movements (opsoclonus) with myoclonus and ataxia
- Adults: associated with breast cancer, SCLC, ovarian cancer
- Children: classically associated with neuroblastoma (~50%)
Key Antibody-Cancer Associations
| Antibody | Median Age | M:F | Clinical Presentation | Cancer (~%) | Immunotherapy Response |
|---|---|---|---|---|---|
| ANNA-1 (Hu) | Mid 60s | 1:1 | Multifocal: sensory neuronopathy, limbic encephalitis, cerebellar ataxia, PEM, dysautonomia | 80% SCLC | 50% improve/stabilize |
| PCA-1 (Yo) | 60s | 1:20 | Progressive cerebellar degeneration | 90% breast/ovarian | Poor; most wheelchair-bound by 3 months |
| CRMP-5 (CV2) | Mid 60s | 1:1.5 | Neuropathy, limbic encephalitis, cerebellar ataxia, optic neuritis, chorea | 80% SCLC | 50% improve/stabilize; median survival 10–20 months |
| Ma2 | Late 30s | 2.3:1 | Limbic/diencephalic/brainstem encephalitis, sleep disorders, narcolepsy | 90% germ cell tumors | 50% improve/stabilize; high mortality |
| KLHL11 | Mid 40s | 99:1 | Rhombencephalitis, hearing loss, tinnitus | 80% germ cell tumors | Poor; 25% improve; 25% mortality at 1 year |
| LUZP4 | Mid 40s | 9:1 | Rhombencephalitis, limbic encephalitis, motor neuronopathy | 85% germ cell tumors | 75% stabilized or improved |
| SOX1 | Mid 60s | 2.3:1 | LEMS, cerebellar ataxia, limbic encephalitis | 90% SCLC | 60% partial remission (LEMS) |
| Amphiphysin | Mid 60s | 1:1.5 | PEM, stiff person spectrum, neuropathy | 80% SCLC/breast | Some improve; 40% wheelchair by 6 months |
| PDE10A | 70s | 1.3:1 | Movement disorder (chorea), encephalopathy | 85% lung/renal/pancreatic | Rare; high mortality |
Diagnostic Approach
PNS-Care Score (2021 Criteria)
| Category | Level | Points |
|---|---|---|
| Clinical phenotype | High-risk phenotype | 3 |
| Intermediate-risk phenotype | 2 | |
| Low/not associated phenotype | 0 | |
| Neural antibody | High-risk antibody | 3 |
| Intermediate-risk antibody | 2 | |
| Low-risk or negative | 0 | |
| Cancer | Found, consistent with phenotype/antibody | 4 |
| Not found, follow-up <2 years | 1 | |
| Not found, >2 years follow-up | 0 |
Diagnostic levels: Definite ≥8 points; Probable 6–7 points; Possible 4–5 points; Non-PNS ≤3 points.
Cancer Screening
Recommended Cancer Screening Strategy
- CT of chest/abdomen/pelvis: First-line for all suspected paraneoplastic syndromes
- PET-CT: If CT negative but high clinical suspicion; may detect occult malignancies
- Directed screening: Pelvic ultrasound/MRI for ovarian tumors (PCA-1); testicular ultrasound for germ cell tumors (Ma2, KLHL11, LUZP4); mammography for breast cancer
- Repeat screening: If initial screening is negative and high clinical suspicion persists, repeat at 3–6 month intervals for at least 2 years
- The antibody profile should guide the cancer search (e.g., ANNA-1 → SCLC; PCA-1 → gynecologic malignancy; Ma2 → testicular seminoma)
Immune Checkpoint Inhibitor-Related Neurotoxicity
The introduction of immune checkpoint inhibitor (ICI) cancer immunotherapy (anti-CTLA-4, anti-PD-1, anti-PD-L1, anti-LAG3) has led to an increase in cancer-related neurologic autoimmunity:
- Mechanisms: ICIs can trigger new paraneoplastic immune responses, potentiate preexisting subclinical autoimmunity, or have direct toxic effects
- CTLA-4 inhibitors are associated with higher frequency of immune-related adverse events (effect at the priming phase)
- PD-1/PD-L1 inhibitors enhance effector T-cell responses at the tissue level
- Common neurologic complications: Myasthenia gravis (may be fulminant), encephalitis, peripheral neuropathy, myositis, meningitis
- Classic paraneoplastic syndromes (cerebellar degeneration, encephalomyelitis) can be triggered or unmasked by ICI therapy
ICI Neurotoxicity Management
- Neurologic immune-related adverse events may necessitate ICI discontinuation
- Treatment: high-dose corticosteroids, IVIg, or PLEX; additional immunosuppression if refractory
- Balancing cancer treatment benefit against neurologic risk requires multidisciplinary decision-making
- Neurologic symptoms can appear at any time during ICI therapy, including months after discontinuation
Treatment Principles
| Priority | Intervention | Rationale |
|---|---|---|
| 1. Tumor removal | Surgery, chemotherapy, radiation as appropriate | Most critical intervention; removes the antigenic stimulus driving the immune response |
| 2. First-line immunotherapy | IV methylprednisolone, IVIg, PLEX | Attempt to halt ongoing immune-mediated damage |
| 3. Second-line immunotherapy | Rituximab (cell-surface antibodies); cyclophosphamide, mycophenolate (intracellular antibodies) | Sustain response; target the appropriate effector mechanism |
The choice between B-cell-directed (rituximab) and T-cell-directed (cyclophosphamide, mycophenolate) immunosuppression should be guided by whether the antibody targets a cell-surface or intracellular antigen. For intracellular antigen syndromes, where CD8+ T cells are the effectors, agents targeting T cells may be more rational than B-cell depletion.
Prognosis
- Prognosis is generally better for cell-surface antibody syndromes (potentially reversible antibody-mediated dysfunction)
- Intracellular antibody syndromes often have poor neurologic outcomes due to irreversible T-cell-mediated neuronal death
- Early tumor identification and treatment is the strongest predictor of neurologic outcome
- Patients with SCLC-associated paraneoplastic syndromes often have a survival paradox: paradoxically longer cancer survival than SCLC patients without paraneoplastic syndromes, likely due to the effective antitumor immune response
References
- Zekeridou A. Paraneoplastic neurologic disorders. Continuum (Minneap Minn). 2024;30(4):1021-1051.
- Graus F, Vogrig A, Muñiz-Castrillo S, et al. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm. 2021;8(4):e1014.
- Titulaer MJ, Soffietti R, Dalmau J, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol. 2011;18(1):19-e3.
- Dalmau J, Graus F. Antibody-mediated encephalitis. N Engl J Med. 2018;378(9):840-851.